Leffler Scott J.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Clover Health Gains After Earning 5-Star CMS Rating. Clover Health stock rose after the company secured a 5-star rating for its PPO plan from CMS for 2027. This top score supports the company's long-term outlook and may help attract new members. The news follows a period where the stock was trading near its 52-week high, reflecting positive market sentiment.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
Transaction History
| MYGN | ▼ Sell | Tax Withholding | 6,217 | $63K | 3/14/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 72,165 | $0 | 3/13/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 12,230 | $153K | 1/29/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 46,095 | $0 | 3/14/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 117,770 | $0 | 1/29/2024 | View on chart |
| CLOV | ▼ Sell | Tax Withholding | 83,538 | $82K | 1/25/2024 | View on chart |
| CLOV | ▲ Buy | Grant | 400,000 | $0 | 10/31/2023 | View on chart |
| CLOV | ▼ Sell | Tax Withholding | 124,002 | $113K | 10/25/2023 | View on chart |
| CLOV | ▼ Sell | Tax Withholding | 387,173 | $422K | 7/25/2023 | View on chart |
| CLOV | ▲ Buy | Grant | 5,042,016 | $0 | 7/25/2022 | View on chart |
| SHC | ▲ Buy | Grant | 37,443 | $0 | 3/2/2022 | View on chart |
| SHC | ▼ Sell | Tax Withholding | 3,894 | $88K | 11/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis
An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.